Adverum Biotechnologies Inc
NASDAQ:ADVM
Intrinsic Value
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. [ Read More ]
The intrinsic value of one
ADVM
stock under the Base Case scenario is
1.76
USD.
Compared to the current market price of 10.19 USD,
Adverum Biotechnologies Inc
is
Overvalued by 83%.
ADVM's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ADVM or that its price is influenced by factors unrelated to fundamentals.
Adverum Biotechnologies Inc's market capitalization is 211.5m USD.
ADVM stock price is 10.19 USD.
ADVM stock (1.76 USD) is 83% less than its price (10.19 USD).
ADVM. Open DCF Valuation
ADVM stock (1.76 USD) is 83% less than its price (10.19 USD). Open Relative Valuation
ADVM has upside potential of 300% compared to the average analyst price target.
Open Wall St Estimates
ADVM's ROE (Return on Equity) has significantly decreased in the last 3 years from -34% to -88%, and is approaching profitability.
ADVM's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -240% to -126%, and is approaching profitability.
ADVM's long-term assets (173m USD) exceed its long-term liabilties (90m USD).
ADVM has negative Operating Income for the last twelve months.
ADVM has negative Net Income for the last twelve months.
ADVM's ROE (Return on Equity) for the past 12 months is negative and is equal to -88%.
ADVM's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -126%.
ADVM has negative Free Cash Flow for the last twelve months.
ADVM has negative three-year average ROE (Return on Equity): -55%. The company is not efficient at transforming stockholders' equity into net income.
ADVM has negative three-year average ROIC (Return on Invested Capital): -147%. The company is not efficient at using invested capital to generate operating income.
ADVM's short-term assets (103m USD) exceed its short-term liabilties (25m USD).
ADVM's D/E (Debt to Equity) is very low and is equal to 0.
ADVM's Altman Z-Score is very low and is equal to -8.87.
Valuation Backtest
Adverum Biotechnologies Inc
Run backtest to discover the historical profit from buying and selling
ADVM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Adverum Biotechnologies Inc
Balance Sheet Decomposition
Adverum Biotechnologies Inc
| Current Assets | 102.8m |
| Cash & Short-Term Investments | 96.5m |
| Other Current Assets | 6.2m |
| Non-Current Assets | 70.2m |
| PP&E | 67m |
| Other Non-Current Assets | 3.2m |
| Current Liabilities | 24.9m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 22.9m |
| Other Current Liabilities | 101k |
| Non-Current Liabilities | 64.6m |
| Other Non-Current Liabilities | 64.6m |
Earnings Waterfall
Adverum Biotechnologies Inc
|
Revenue
|
3.6m
USD
|
|
Operating Expenses
|
-127.4m
USD
|
|
Operating Income
|
-123.8m
USD
|
|
Other Expenses
|
6.6m
USD
|
|
Net Income
|
-117.2m
USD
|
Free Cash Flow Analysis
Adverum Biotechnologies Inc
ADVM Profitability Score
Profitability Due Diligence
Adverum Biotechnologies Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Adverum Biotechnologies Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
ADVM Solvency Score
Solvency Due Diligence
Adverum Biotechnologies Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Adverum Biotechnologies Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADVM Price Targets Summary
Adverum Biotechnologies Inc
According to Wall Street analysts, the average 1-year price target for
ADVM
is 40.8 USD
with a low forecast of 20.2 USD and a high forecast of 63 USD.
Ownership
ADVM Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ADVM Price
Adverum Biotechnologies Inc
| Average Annual Return | -18.08% |
| Standard Deviation of Annual Returns | 73.21% |
| Max Drawdown | -98% |
| Market Capitalization | 211.5m USD |
| Shares Outstanding | 20 754 900 |
| Percentage of Shares Shorted | 4.46% |
Company Profile
Adverum Biotechnologies Inc
Country
Industry
Market Cap
Dividend Yield
Description
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2014-07-31. The firm develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The firm's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Contact
IPO
Employees
Officers
The intrinsic value of one
ADVM
stock under the Base Case scenario is
1.76
USD.
Compared to the current market price of 10.19 USD,
Adverum Biotechnologies Inc
is
Overvalued by 83%.
You don't have any saved screeners yet
